A. Alexandru

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

Diagnosis and treatment protocols of cutaneous melanoma: latest approach 2010.

A. Alexandru, D. Dumitrescu, I. Petrescu, 2010, Chirurgia.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

Split course radiation with concurrent vinorelbine and cisplatin in locally advanced non-small cell lung cancer. A phase II study.

C. Cornila, A. Alexandru, M. Dediu, 2004, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.

A. Alexandru, M. Dediu, A. Tarlea, 2009, Lung cancer.

Compliance with adjuvant chemotherapy in non-small cell lung cancer. The experience of a single institution evaluating a cohort of 356 patients.

R. Anghel, A. Alexandru, M. Dediu, 2006, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

K. Syrigos, Keunchil Park, H. Borghaei, 2020 .

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

A Rare Case of a Testicular Teratoma Associated with a Neuroendocrine Tumour.

A. Alexandru, A. Marincaş, E. Brătucu, 2019, Chirurgia.

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

S. Thongprasert, R. Gaafar, M. Schenker, 2019, Lung cancer management.

Anthracycline pretreated patients: who is who in the chemotherapy choice of relapsed breast cancer?

A. Alexandru, M. Dediu, D. Median, 2005, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Pemetrexed in non-small-cell lung cancer

A. Alexandru, M. Dediu, Florentina Bratu, 2014 .

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.

R. Anghel, A. Alexandru, M. Dediu, 2005, Lung cancer.

Clinical Outcomes, Treatment and Testing Patterns in Patients with Advanced Non-Small Lung Cell Cancer with Epidermal Growth Factor Receptor Mutations: Results of the Romanian Cohort From a Multi-national Retrospective Chart Review (REFLECT)

T. Ciuleanu, A. Alexandru, M. Dediu, 2022, Journal of Medical and Radiation Oncology.

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

F. Guisier, T. Cascone, A. Alexandru, 2024, Journal of Clinical Oncology.